Markets:

Overview

News

Currencies

International

Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

535.74 -0.66 (-0.12%)

Delayed Quote Updated: 9:41 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Top Peter Lynch-Style GARP Investment ↗

September 17, 2025

United Therapeutics (UTHR) aligns with Peter Lynch's GARP strategy, featuring strong EPS growth, a PEG below 1, zero debt, and robust financial health.

Via Chartmill

United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum

September 16, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress

September 12, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results ↗

September 10, 2025

United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one.

Via Investor's Business Daily

Topics ETFs

MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results ↗

September 02, 2025

Via Stocktwits

This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside ↗

September 02, 2025

Via Stocktwits

MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together ↗

August 27, 2025

Via Stocktwits

Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio? ↗

September 07, 2025

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

Via Benzinga

United Therapeutics Corp (NASDAQ:UTHR): A Prime Value Investing Candidate with Strong Fundamentals ↗

September 06, 2025

United Therapeutics (UTHR) is a strong value investing candidate with low P/E, zero debt, high profitability, and excellent financial health, offering a solid margin of safety.

Via Chartmill

Here are the top movers in Tuesday's session. ↗

September 02, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 02, 2025

Via Benzinga

Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results ↗

September 02, 2025

Via Benzinga

Topics Stocks

Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session. ↗

September 02, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

Why Is United Therapeutics Stock Rallying On Tuesday? ↗

September 02, 2025

United Therapeutics' Tyvaso showed significant lung function improvement in IPF patients, with plans to seek FDA approval for expanded use.

Via Benzinga

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

September 02, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It ↗

September 02, 2025

The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition.

Via Investor's Business Daily

Tuesday's pre-market session: top gainers and losers ↗

September 02, 2025

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 02, 2025

Via Benzinga

United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis

September 02, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

August 29, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corp. (NASDAQ:UTHR) Embodies Peter Lynch's GARP Strategy ↗

August 27, 2025

United Therapeutics (UTHR) exemplifies Peter Lynch's GARP strategy with strong EPS growth, zero debt, and an undervalued PEG ratio. A model for long-term investors.

Via Chartmill

2 Mid-Cap Stocks with Competitive Advantages and 1 Facing Headwinds

August 27, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

3 Market-Beating Stocks to Consider Right Now

August 26, 2025

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends...

Via StockStory

2 Profitable Stocks to Keep an Eye On and 1 That Underwhelm

August 25, 2025

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

August 19, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.

Via StockStory

Topics Artificial Intelligence

1 Growth Stock to Stash and 2 Facing Challenges

August 19, 2025

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Via StockStory

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Prime Value Investment with Strong Fundamentals and Undervalued Potential ↗

August 15, 2025

UNITED THERAPEUTICS CORP (UTHR) is a strong value investing pick with low P/E ratios, zero debt, and high profitability, trading below its true worth. Ideal for investors seeking undervalued biotech...

Via Chartmill

UTHR Q2 Deep Dive: Tyvaso DPI Drives Growth Amid Pipeline and Competitive Uncertainty

August 12, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its non-GAAP profit of $6.41 per...

Via StockStory

Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It ↗

August 12, 2025

The company is working through a patent battle that could seriously hamper sales of its new drug.

Via Investor's Business Daily

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.